Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFOXIRI followed by chemoradiotherapy for high-risk locally advanced rectal cancer
NL-OMON28766Recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Jun 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fluorouracil, oxaliplatin, folinic acid and irinotecan in rectal cancer, sponsored by Catharina Ziekenhuis. Primary endpoint: Combined pathological complete response and sustained clinical complete response rate. Started Jun 2021; status: recruiting.
02
Drugs
fluorouraciloxaliplatinfolinic acidirinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NL-OMON28766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28766.